Why are Laurus Labs shares up over 2% today? Explained
Shares of Laurus Labs Ltd surged over 2% to ₹856.25 in early trade on Monday, making it one of the top gainers on the NSE. The sharp upmove comes on the back of a stellar Q1 performance, a major land allotment for expansion, and bullish commentary from top brokerages. Here's what's driving the stock higher: 1. Blockbuster Q1 FY26 Results
Laurus Labs posted a net profit of ₹163 crore, up a massive 1,185% YoY from ₹13 crore a year ago. Revenue : ₹1,570 crore (up 31% YoY)
: ₹1,570 crore (up 31% YoY) EBITDA : ₹389 crore (up 127% YoY)
: ₹389 crore (up 127% YoY) EBITDA Margin: Expanded significantly YoY, reflecting strong operating leverage
This marked the company's third consecutive earnings beat, with particularly robust performance in the CDMO (Contract Development and Manufacturing Organization) and ARV (antiretroviral) verticals. 2. Strategic Land Allotment for Laurus Pharma Zone
The Andhra Pradesh government allotted 531.77 acres to Laurus in IP Rambilli Phase-II (Anakapalli District) for the development of a Laurus Pharma Zone (LPZ). Planned investment : ₹5,630 crore
: ₹5,630 crore Job creation target : 6,350 people
: 6,350 people Phased execution over 8 years
This land is crucial for Laurus' long-term growth strategy, giving it the physical base to scale up manufacturing capabilities across API, formulations, and novel therapies. 3. Bullish Broker Commentary Motilal Oswal (MOSL) has maintained a 'Buy' rating, raising the target price to ₹970 (from ₹860) Upgraded gross margin guidance to 55–60% (from 50–55%) Strong CDMO visibility and pipeline Raised earnings estimates by 16% for FY26 and 7% for FY27
has maintained a rating, raising the (from ₹860) Antique Stock Broking gave a more balanced view, maintaining a 'Hold' but still raising the target to ₹700 (from ₹520), citing: Limited visibility in CDMO contracts ARV outlook steady but not exceptional Scale-up challenges in Bio CDMO segment
gave a more balanced view, but still raising the target to ₹700 (from ₹520), citing:
Still, the firm expects ~16% revenue CAGR from FY25 to FY28, and EBITDA margins to rise from 19% to 30% over the same period. Segmental Strength & Capex Plans The CDMO business is growing rapidly , now contributing more meaningfully to revenues
, now contributing more meaningfully to revenues The company is also building a new Gene/ADC facility in Hyderabad and a microbial fermentation plant in Vizag
and a Plans to invest ₹5,000 crore over the next 5 years, with net debt/EBITDA expected to stay in the 2.2x–2.5x range Market Snapshot: Stock Price : ₹856.25 (up 2.21%)
: ₹856.25 (up 2.21%) 52-week range : ₹417.70 – ₹855.00
: ₹417.70 – ₹855.00 Market Cap : ₹460.32 billion
: ₹460.32 billion P/E Ratio: 90.53
Laurus Labs' sharp rally today is driven by optimism around its blockbuster Q1 numbers, the government-backed land allotment, and analyst upgrades, all of which point to a long runway for growth. While near-term execution challenges remain, the market appears to be betting on Laurus' transformational expansion strategy and strong positioning in high-value pharma segments.
Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Please consult your financial advisor before making any investment decisions.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
15 minutes ago
- Bloomberg
Indian Stock Futures, Offshore Rupee Slide on 25% Trump Tariff
Indian stock futures slid and the rupee dropped offshore on Wednesday after US President Donald Trump said he would impose a tariff rate of 25% along with an additional penalty on imports from the world's fastest growing major economy. While the announcement came after Indian markets had closed, NSE Nifty 50 future contracts traded at GIFT City fell as much as 0.5%, erasing earlier gains of 0.4%. The dollar/rupee one-month forward was up 0.9% to 88, pushing the pair to its highest since February, according to data compiled by Bloomberg. The iShares MSCI India stocks ETF, which trades in the US, was down over 1%.
Business Upturn
2 hours ago
- Business Upturn
Trump Imposes 25% Tariff On India: GIFT Nifty falls 180 points sharply post announcement
By Aditya Bhagchandani Published on July 30, 2025, 17:53 IST In a major blow to market sentiment, GIFT Nifty witnessed a sharp fall late Wednesday, tumbling over 150 points after former U.S. President Donald Trump announced a 25% tariff on Indian imports, citing India's continued energy and defense cooperation with Russia. At 17:49 IST, the GIFT Nifty dropped to 24,700.50, down 153.50 points (-0.62%), with a steep red candlestick indicating heavy selling pressure. Trump's Tariff Trigger: Russian Oil and Arms Purchases Trump took to his Truth Social platform to declare: 'India continues to buy huge amounts of oil and military equipment from Russia. This must stop. Starting August 1, a 25% tariff plus an additional penalty will apply to all Indian goods entering the U.S.' This unexpected announcement marks a major pivot in U.S.-India trade relations. The 'penalty tariff' will reportedly be levied on top of existing duties, targeting key Indian export sectors such as textiles, pharmaceuticals, and IT services, which collectively generate billions in annual trade. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 hours ago
- Business Upturn
ITD Cementation Q1 Results: Net Profit jumps 37% YoY to Rs 137.2 crore
Infrastructure major ITD Cementation India Ltd reported a consolidated net profit of ₹137.2 crore for the quarter ended June 30, 2025 (Q1 FY26), marking a strong 37% year-on-year (YoY) increase from ₹100.2 crore reported in Q1 FY25. The company also posted total income of ₹2,556.9 crore, up 6.7% YoY from ₹2,397.4 crore in the same quarter last year, driven by steady execution across its order book, especially in marine, urban infrastructure, and metro rail segments. Key Highlights – Q1 FY26 (Consolidated) Net Profit: ₹137.2 crore vs ₹100.2 crore YoY (▲37%) Total Income: ₹2,556.9 crore vs ₹2,397.4 crore YoY (▲6.7%) EBITDA (excluding other income): ₹280.6 crore vs ₹241.8 crore YoY (▲16%) Profit Before Tax (PBT): ₹163.5 crore vs ₹135.1 crore YoY (▲21%) Total Expenses: ₹2,400.4 crore vs ₹2,267.3 crore YoY The company saw a moderation in subcontracting and material costs compared to the previous quarter, improving its operational margin. Finance costs stood at ₹49.8 crore, slightly lower than the ₹52.9 crore incurred in the same quarter last year. ITD Cementation's share of profits from joint ventures also contributed positively at ₹7.05 crore, reversing the trend from a loss in the previous quarter. Outlook The company remains optimistic about order inflow momentum, citing a strong pipeline in marine, water infrastructure, and metro rail EPC projects. Management reaffirmed its focus on timely execution, cost control, and cash flow management to maintain profitability and working capital discipline. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
